Cargando…

Real world studies are essential for drug therapy in Parkinson’s disease

Detalles Bibliográficos
Autor principal:	Müller, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2018
Materias:	Perspective
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6126119/ https://www.ncbi.nlm.nih.gov/pubmed/30127111 http://dx.doi.org/10.4103/1673-5374.237118

Ejemplares similares

Cell Therapies for Parkinson's Disease
por: Irion, Stefan
Publicado: (2019)

Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson’s Patients Using Digital Mobility Outcomes
por: Viceconti, Marco, et al.
Publicado: (2020)

Response to “Oral Chaperone Therapy Migalastat for the Treatment of Fabry Disease: Potentials and Pitfalls of Real‐World Data”
por: Müntze, Jonas, et al.
Publicado: (2019)

A Drug Is not an Outcome: Extending Translation Through Implementation Using Real‐World Data
por: Shaywitz, David A.
Publicado: (2019)

Real-World Evidence for Equality
por: Johnson, C. Erwin, et al.
Publicado: (2021)

Real-World Longitudinal Experience of Botulinum Toxin Therapy for Parkinson and Essential Tremor
por: Samotus, Olivia, et al.
Publicado: (2022)

Potential role of biofeedback therapy for Parkinson’s disease
por: Kotani, Naoya, et al.
Publicado: (2021)

Smog, Cognition and Real-World Decision-Making
por: Chen, Xi
Publicado: (2018)

Targeting chaperone-mediated autophagy for Parkinson’s disease therapy
por: Wang, Yi-Ting, et al.
Publicado: (2023)

Designing nanocarriers to overcome the limitations in conventional drug administration for Parkinson’s disease
por: García-Muñoz, Rafael A., et al.
Publicado: (2022)

New perspectives in iron chelation therapy for the treatment of Parkinson’s disease
por: Nuñez, Marco T., et al.
Publicado: (2019)

Real‐World Data: An Unrealized Opportunity in Global Health?
por: Barrett, Jeffrey S., et al.
Publicado: (2019)

Gene therapy in Parkinson's disease: targeting the endplasmic reticulum proteostasis network
por: Castillo, Valentina, et al.
Publicado: (2015)

Why and how does light therapy offer neuroprotection in Parkinson's disease?
por: Mitrofanis, John
Publicado: (2017)

Induced pluripotent stem cells for modeling and cell therapy of Parkinson's disease
por: Csöbönyeiová, Mária, et al.
Publicado: (2016)

The Advantages and Challenges of Using Real‐World Data for Patient Care
por: Ho, Yunn‐Fang, et al.
Publicado: (2019)

Drug therapy in patients with Parkinson’s disease
por: Müller, Thomas
Publicado: (2012)

Challenges and Solutions for Collecting and Analyzing Real World Data: The Eric CLL Database as an Illustrative Example
por: Chatzidimitriou, Anastasia, et al.
Publicado: (2020)

Improving Realism in Clinical Trial Simulations via Real‐World Data
por: Kimko, Holly, et al.
Publicado: (2017)

An Evaluative Review of Barriers to Critical Thinking in Educational and Real-World Settings
por: Dwyer, Christopher P.
Publicado: (2023)

Alpha-synuclein preformed fibrils: a tool to understand Parkinson’s disease and develop disease modifying therapy
por: Chmielarz, Piotr, et al.
Publicado: (2021)

“Generality of mis-fit”? The real-life difficulty of matching scales in an interconnected world
por: Keskitalo, E. Carina H., et al.
Publicado: (2016)

Preparing for genomic medicine: a real world demonstration of health system change
por: Gaff, Clara L., et al.
Publicado: (2017)

Real‐World Data for Regulatory Decision Making: Challenges and Possible Solutions for Europe
por: Cave, Alison, et al.
Publicado: (2019)

Deep learning and alternative learning strategies for retrospective real-world clinical data
por: Chen, David, et al.
Publicado: (2019)

Optimal invasive species surveillance in the real world: practical advances from research
por: Koch, Frank H., et al.
Publicado: (2020)

Real‐World Evidence in EU Medicines Regulation: Enabling Use and Establishing Value
por: Arlett, Peter, et al.
Publicado: (2021)

Mitochondrial-Derived Vesicles as Candidate Biomarkers in Parkinson’s Disease: Rationale, Design and Methods of the EXosomes in PArkiNson Disease (EXPAND) Study
por: Picca, Anna, et al.
Publicado: (2019)

Mitochondria in the context of Parkinson's disease
por: Villacé, Patricia, et al.
Publicado: (2017)

Falling upward with Parkinson’s disease
por: Buetow, Stephen A., et al.
Publicado: (2017)

Real-World Evidence in Support of Oncology Product Registration: A Systematic Review of New Drug Application and Biologics License Application Approvals from 2015–2020
por: Arondekar, Bhakti, et al.
Publicado: (2022)

The Michael J. Fox Foundation’s Strategies for Accelerating Translation of LRRK2 into Therapies for Parkinson Disease
por: Padmanabhan, Shalini, et al.
Publicado: (2020)

International Collaboration in Real‐World Evidence Generation for Direct Acting Oral Anti‐Coagulants
por: Arlett, Peter, et al.
Publicado: (2020)

A Real‐World Evidence Framework for Optimizing Dosing in All Patients With COVID‐19
por: Peck, Richard W., et al.
Publicado: (2020)

COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
por: Sulzer, David, et al.
Publicado: (2020)

Using multi-organ culture systems to study Parkinson’s disease
por: Reiner, Orly, et al.
Publicado: (2020)

Efficacy of cognitive rehabilitation in Parkinson's disease
por: Díez-Cirarda, María, et al.
Publicado: (2018)

Genetic Analysis of Pathways to Parkinson Disease
por: Hardy, John
Publicado: (2010)

Parkinson’s disease-associated melanin steal
por: Hinz, Marty, et al.
Publicado: (2014)

Parkinson’s disease: carbidopa, nausea, and dyskinesia
por: Hinz, Marty, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v3u6apiall7vh7qe35dhtbug76